2021
How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCareCombined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, Kinahan C, Francescone MM, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov AR, O’Connor O. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 2021, 137: 2161-2170. PMID: 33171487, DOI: 10.1182/blood.2020009004.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaOverall response rateMedian progression-free survivalProgression-free survivalT-cell lymphomaOverall survivalR Peripheral T Cell LymphomaResponse rateFollicular helper cell phenotypeMulticenter phase 2 studyHigher overall response rateFrequent grade 3Complete response rateComplete remission ratePhase 2 studyPhase 1 trialDuration of responseHelper cell phenotypeLonger median survivalHistone deacetylase inhibitorsPTCL patientsR diseaseTreatment-naïveMedian survivalRemission rate
2020
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas
Leeman-Neill RJ, Soderquist CR, Montanari F, Raciti P, Park D, Radeski D, Mansukhani MM, Murty VV, Hsiao S, Alobeid B, Bhagat G. Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. Haematologica 2020, 107: 201-210. PMID: 33297669, PMCID: PMC8719101, DOI: 10.3324/haematol.2020.267294.Peer-Reviewed Original ResearchConceptsPlasmablastic lymphomaJAK/STATSolid organ allograft recipientsTargetable oncogenic pathwaysOrgan allograft recipientsAllograft recipientsComprehensive histopathologicEBV infectionHIV infectionPlasmablastic myelomaClinical outcomesClinicopathologic featuresYears postdiagnosisAggressive neoplasmDisease subsetsEBV- casesImmunophenotypic heterogeneityImmunophenotypic evaluationMAP kinaseImmunocompromised individualsMYC rearrangementDisease pathogenesisPhenotypic spectrumNotch pathway genesOncogenic pathways
2019
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
O’Connor O, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone MM, Nandakumar R, Soderquist CR, Park DC, Bhagat G, Cheng B, Risueño A, Menezes D, Shustov AR, Sokol L, Scotto L. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood 2019, 134: 1395-1405. PMID: 31471376, DOI: 10.1182/blood.2019001285.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaPhase 1 studyDay 1Day 8Response rateMulticenter phase 1 studyT-cell lymphoma patientsAdvanced lymphoid malignanciesTreatment-related deathsComplete response rateCoprimary end pointsGrade 3 thrombocytopeniaGrade 4 neutropeniaGrade 4 thrombocytopeniaOverall response rateT-cell lymphomaNon-T-cell lymphomasTumor mutational profileHistone deacetylase inhibitorsPTCL patientsPleural effusionLymphoma patientsLymphoid malignanciesEpigenetic modifiersPatients
2015
Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series
Montanari F, Radeski D, Seshan V, Alobeid B, Bhagat G, O'Connor OA. Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series. British Journal Of Haematology 2015, 171: 491-500. PMID: 26250758, DOI: 10.1111/bjh.13621.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedChildChild, PreschoolCombined Modality TherapyEpstein-Barr Virus InfectionsFemaleHumansImmunosuppressive AgentsInfantLymphoproliferative DisordersMaleMiddle AgedMultivariate AnalysisOrgan TransplantationPostoperative ComplicationsPrognosisRisk AssessmentRituximabSeverity of Illness IndexYoung AdultConceptsPost-transplant lymphoproliferative disorderECOG scoreElderly patientsPediatric patientsLymphoproliferative disordersEastern Cooperative Oncology Group scoreECOG score 0Setting of immunosuppressionDecade of diagnosisNew prognostic scoreSingle-institution seriesHigh-risk groupAdult patientsOverall survivalPrognostic factorsPrognostic scoreInstitution seriesSingle institutionScore 0Tissue allograftsPatientsLarge seriesRisk categoriesHeterogeneous groupRecursive partitioning model
2010
Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma
Lipstein M, O'Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2010, 10: e43-e46. PMID: 21856550, DOI: 10.3816/clml.2010.n.074.Peer-Reviewed Original ResearchConceptsTumor lysis syndromePlasmablastic lymphomaLysis syndromeHIV-negative plasmablastic lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaBortezomib-based treatmentHIV-negative patientsDramatic clinical responseB-cell lymphomaWorld Health OrganizationClinical responseImmunocompetent patientsAggressive lymphomaRare lymphomaMultiple myelomaOptimal treatmentLymphomaPatientsHealth OrganizationSyndromeStandard recommendationsTreatmentMyelomaSubtypesMonomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disorders
Montanari F, Bhagat G, Clark-Garvey S, Seshan V, Zain J, Diefenbach C, Mccormick E, Crook M, Conroy M, O'connor OA. Monomorphic T-cell post-transplant lymphoproliferative disorders exhibit markedly inferior outcomes compared to monomorphic B-cell post-transplant lymphoproliferative disorders. Leukemia & Lymphoma 2010, 51: 1761-1764. PMID: 20807097, DOI: 10.3109/10428194.2010.500436.Peer-Reviewed Original ResearchBone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors
Montanari F, O'Connor OA, Savage DG, Zain JM, Venkatraman S, McCormick EK, Crook MT, Tsao L, Sevilla DW, Bhagat G, Alobeid B. Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors. Human Pathology 2010, 41: 1150-1158. PMID: 20381113, DOI: 10.1016/j.humpath.2009.11.016.Peer-Reviewed Original ResearchConceptsMonomorphic posttransplant lymphoproliferative disorderPosttransplant lymphoproliferative disorderBone marrow involvementPolymorphic posttransplant lymphoproliferative disordersDiffuse large B-cell lymphomaLarge B-cell lymphomaMarrow involvementLymphoproliferative disordersB-cell lymphomaSerologic parametersEpstein-Barr virus statusPosttransplant lymphoproliferative disorder patientsDe novo diffuse large B-cell lymphomaNovo diffuse large B-cell lymphomaBone marrow examinationElevated lactate dehydrogenaseBone marrow biopsyHodgkin lymphoma typeDiffuse large B-cell lymphoma casesLarge B-cell lymphoma casesB-cell lymphoma casesSensitive screening toolStaging biopsiesExtranodal involvementMarrow examination
2007
Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy
Arcaini L, Burcheri S, Rossi A, Pascutto C, Passamonti F, Brusamolino E, Paulli M, Orlandi E, Buelli M, Viero P, Lucioni M, Montanari F, Merli M, Cortelazzo S, Lazzarino M. Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy. Clinical Cancer Research 2007, 13: 182-186. PMID: 17200353, DOI: 10.1158/1078-0432.ccr-06-0703.Peer-Reviewed Original ResearchConceptsStandardized incidence ratiosMarginal zone B-cell lymphomaIncidence ratiosSecond cancersB-cell lymphomaLymphoid tissueGeneral populationSolid tumorsSkin cancerMucosa associated lymphoid tissueSex-specific incidence ratesSite of cancerNonmelanoma skin cancerMarginal zone lymphomaSitu skin cancersNongastric MALT lymphomasExtranodal sitesAdditional malignanciesPrevious malignancyCancer RegistryComparison of risksSecond tumorMALT lymphomaIncidence rateHematologic diseases
2006
Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease
Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M, Linfomi I. Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease. British Journal Of Haematology 2006, 136: 301-304. PMID: 17233821, DOI: 10.1111/j.1365-2141.2006.06437.x.Peer-Reviewed Original ResearchConceptsFollicular Lymphoma International Prognostic IndexOverall survivalClinical featuresPrimary nodal marginal zone B-cell lymphomaHepatitis C virus serologyMarginal zone B-cell lymphomaNodal marginal zone B-cell lymphomaC virus serologyStage IV diseaseWorse overall survivalInternational Prognostic IndexB-cell lymphomaWorse OSPrognostic indexVirus serologyPrognostic assessmentRare diseaseMultivariate analysisLactate dehydrogenaseDiseasePatientsPrognosisLymphomaSerologyNongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination
Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. The Oncologist 2006, 11: 285-291. PMID: 16549813, DOI: 10.1634/theoncologist.11-3-285.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnthracyclinesAntibodies, MonoclonalAntigens, CD20Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow NeoplasmsChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansItalyLymphatic MetastasisLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedMultivariate AnalysisPrognosisRadiotherapy, AdjuvantRetrospective StudiesConceptsBone marrow involvementMarrow involvementNodal involvementClinical featuresSurvival timeBone marrowMedian event-free survival timeB-cell MALT lymphomaMedian overall survival timeDisease disseminationEvent-free survival timeB-cell mucosaStage IV diseaseOverall survival timeLymphoid tissue lymphomaMarginal zone lymphomaLonger EFSNodal diseaseShorter OSOS timeTissue lymphomaWaldeyer's ringPoor outcomePrognostic significancePrognostic valueRole of the molecular staging and response in the management of follicular lymphoma patients
Arcaini L, Colombo N, Bernasconi P, Calatroni S, Passamonti F, Orlandi E, Bonfichi M, Burcheri S, Della Porta M, Rumi E, Montanari F, Algarotti A, Pascutto C, Lazzarino M. Role of the molecular staging and response in the management of follicular lymphoma patients. Leukemia & Lymphoma 2006, 47: 1018-1022. PMID: 16840191, DOI: 10.1080/10428190500467834.Peer-Reviewed Original ResearchConceptsBcl-2/IgH rearrangementBcl-2 rearrangementBcl-2-negative patientsBcl-2 positive patientsPeripheral bloodMedian EFSMolecular respondersBone marrowNegative patientsPositive patientsClinical featuresBetter EFSIgH rearrangementsMedian event-free survivalBcl-2 negative casesEvent-free survivalFirst-line therapyCohort of patientsFollicular lymphoma patientsBcl-2Onset of diseaseMolecular responseBcl-2-positive casesInitial stagingLymphoma patients
2005
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment
Arcaini L, Colombo N, Passamonti F, Burcheri S, Orlandi E, Brusamolino E, Della Porta M, Rumi E, Montanari F, Pascutto C, Paulli M, Lazzarino M. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leukemia Research 2005, 30: 277-282. PMID: 16112730, DOI: 10.1016/j.leukres.2005.07.006.Peer-Reviewed Original ResearchConceptsFLIPI scorePeriod of diagnosisHigh-risk groupFollicular lymphomaIntermediate riskLower riskRisk groupsMedian OSIPI scorePrognostic categoriesPoor-risk groupSubset of patientsSurvival of patientsTime of diagnosisFollicular lymphoma patientsUse of anthracyclinesDistribution of patientsType of treatmentIndependent seriesIndolent outcomeClinical characteristicsIndolent disorderPrognostic scorePrognostic indexWorse prognosis